Year
2012
Status
Exited
Team
Field
Cardiovascular therapeutic
Location
Amsterdam (The Netherlands)
Fund
BGV II
Dezima Pharma
Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease. DEzima Pharma was acquired by Amgen in 2015.